Centiva Capital, LP Altimmune, Inc. Transaction History
Centiva Capital, LP
- $4.79 Billion
- Q3 2024
A detailed history of Centiva Capital, LP transactions in Altimmune, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 19,607 shares of ALT stock, worth $165,875. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,607Holding current value
$165,875% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALT
# of Institutions
183Shares Held
38.9MCall Options Held
873KPut Options Held
695K-
Black Rock Inc. New York, NY5.32MShares$45 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.98MShares$42.2 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.88MShares$32.8 Million0.01% of portfolio
-
State Street Corp Boston, MA3.41MShares$28.9 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$23.3 Million1.44% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $415M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...